Strategy to Submission: Drug Development from Planning Through Regulatory Approval

Jordan Lateiner, VP of Portfolio and Program Management at Syndax, opens the Philadelphia PPM Summit with a keynote that traces the full arc of drug development from initial strategic planning through regulatory approval and submission. In an industry where development timelines span years and investments reach billions, the quality of portfolio and program management can mean the difference between a successful launch and a costly failure.

Jordan will share insights from his experience at Syndax on how to build integrated planning frameworks that connect early-stage research decisions to downstream regulatory and commercial milestones. The session will address how leading pharma organizations are using portfolio management to accelerate time-to-market while managing the inherent risks of drug development.

This keynote will provide a strategic foundation for the conference, framing the key challenges and opportunities that will be explored in greater depth throughout the two-day program.